Lilly Announces Major China R&D Center

Eli Lilly will build a bricks and mortar center dedicated to R&D work on diabetes in Shanghai. The center represents a major strategic departure for Lilly, which has touted its partnership approach with China’s innovative life science community. Lilly says diabetes in China, which has reached epidemic proportions, has a different molecular structure than diabetes elsewhere in the world. The company hopes to discover innovative solutions to the disease. More details... Stock Symbol: (NYSE: LLY)